TGA Defends COVID-19 Vaccine Safety Amid Spike Protein Concerns

During my session with the Therapeutic Goods Administration (TGA) at Senate Estimates in November, I questioned them about a number of concerns.

Does the TGA agree that spike protein is pathogenic in COVID-19 vaccines? Professor Langham clarified that the spike protein is not pathogenic and is designed to trigger an antigen recognition and antibody response.

Has the TGA observed or seen reports of any adverse events related to the spike protein? Professor Langham responded that no such events have been observed, as the spike protein is quickly degraded by the body once it's introduced s part of the mRNA vaccine.

What analysis did the TGA conduct regarding the spike protein's suitability before vaccine approval? Professor Lawler agreed to provide detailed information on notice.

It has been demonstrated that spike proteins exert an inhibitory effect on the function of the angiotensin-converting enzyme 2 (ACE2), leading to dysregulation of the renin-angiotensin system. Is the TGA aware of this effect of spike proteins on ACE2 and on the renin-angiotensin system? Professor Langham explained that while the spike protein attaches to receptors, it does not cause harm on its own.

Is 'long COVID' the result of spike protein in the body coming from the Wuhan and alpha versions of COVID itself or is it from the vaccine products containing spike proteins, which are injected repeatedly in Australians? Professor Lawler responded that there is no accepted evidence to confirm such a link.

Has the TGA received any applications for treatments to remove spike proteins from the body and has the TGA engaged with research institutions on this matter? Professor Lawler clarified that the TGA has not received such applications, does not commission research, and focuses on regulating therapeutic goods.

The TGA emphasised that the overall risk-benefit profile of COVID-19 vaccines remains positive.

Transcript: https://www.malcolmrobertsqld.com.au/tga-defends-covid-19-vaccine-safety-amid-spike-protein-concerns/